Chemical Namepasereotide
Dosage FormInjection (subcutaneous; 0.3 mg/mL, 0.6 mg/mL, 0.9 mg/mL)
Drug ClassAnalogs
Approval Year2012


  • For the treatment of Cushing’s disease for whom pituitary surgery is not an option or has not been curative in adult patients.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Signifor (pasereotide) Prescribing Information2012Novartis Pharmaceuticals Corporation, East Hanover, NJ
Document TitleYearSource
Treatment of cushing’s syndrome: An endocrine society clinical practice guideline.2015The Journal of Clinical Endocrinology & Metabolism